FrancophonIA/ELRC3.0 huggingface dataset:
English: Studies in animals have shown that ioflupane binds with high affinity to the presynaptic dopamine transporter and so radiolabelled ioflupane (
Estonian: Loomkatsetes on näidatud, et joflupaanil on kõrge afiinsus presünaptilise dopamiini transportija suhtes, mis võimaldab radioaktiivselt märgistatud joflupaani (
English: Analyses in which both possible and probable DLB patients were compared with nonDLB dementia patients demonstrated values for the sensitivity of ioflupane (
Estonian: Analüüsides, milles võimaliku ja tõenäolise Lewy kehade dementsusega patsiente võrreldi muu kui Lewy kehade dementsusega patsientidega, olid joflupaani (
English: 2.5 mL vial 35 hours from the end of synthesis (7 hours from the activity reference time stated on the label)
Estonian: 35 tundi alates sünteesi lõpust (7 tundi alates referentsajal mõõdetud aktiivsusest, mis on märgitud pakendile)
English: As the effective dose is 4.6 mSv when the maximal recommended activity of 185 MBq is administered these adverse events are expected to occur with a low probability.
Estonian: Et maksimaalse soovitatava radioaktiivse annuse 185 MBq manustamisel on efektiivne doos 4,6 mSv, on nende kõrvaltoimete tekkimise tõenäosus väike.
English: Precautions to be taken before handling or administering the medicinal product Striascan should be used without dilution.
Estonian: Enne ravimi käsitsemist või manustamist tuleb järgida ettevaatusabinõusid Striascani tuleb kasutada ilma lahjendamata.
English: Striascan is given to you as an injection, usually into a vein in your arm. A single injection is enough.
Estonian: Striascani manustatakse teile süstina, tavaliselt käsivarreveeni.
English: Driving and using machines It is considered unlikely that Striascan will affect your ability to drive or to use machines.
Estonian: Autojuhtimine ja masinatega töötamine Ei peeta tõenäoliseks, et Striascan mõjutaks autojuhtimise ja masinate käsitsemise võimet.
English: The nuclear medicine doctor supervising the procedure will decide on the quantity of Striascan to be used in your case.
Estonian: Protseduuri kontrolliv nukleaarmeditsiini arst valib Striascani koguse, mida teie korral kasutatakse.
English: What Striascan is and what it is used for
Estonian: Mis ravim on Striascan ja milleks seda kasutatakse
English: 5 mL vial 48 hours from the end of synthesis (20 hours from the activity reference time stated on the label)
Estonian: 48 tundi alates sünteesi lõpust (20 tundi alates referentsajal mõõdetud aktiivsusest, mis on märgitud pakendile)
English: Active substances that bind to the dopamine transporter with high affinity may therefore interfere with Striascan diagnosis.
Estonian: Joflupaan seondub dopamiini transportijaga, mistõttu dopamiini transportija suhtes kõrget afiinsust omavad toimeained võivad mõjustada Striascani abil tehtavat diagnoosimist.
English: Talk to your nuclear medicine doctor before using this medicine if you have moderate or severe problems with your kidneys or liver.
Estonian: Enne selle ravimpreparaadi kasutamist pidage nõu oma nukleaarmeditsiini arstiga, kui teil on mõõdukas või raske neeru- või maksakahjustus.
English: 15 mL amber glass vial sealed with a rubber closure and metal overseal.
Estonian: 15 ml merevaiguvärvi klaasist viaal, mis on suletud kummikorgi ja metallsulguriga.
English: I) results in an absorbed dose to the uterus of 2.6 mGy.
Estonian: I) manustamisel on imendunud annus emakas 2,6 mGy.
English: - The other ingredients are acetic acid, glacial (E 260); sodium acetate trihydrate (E 262), ethanol, anhydrous (E 1510); phosphoric acid, concentrated (E 338) and water for injections.
Estonian: • Teised koostisosad on jää-äädikhape (E 260); naatriumatsetaattrihüdraat (E 262), veevaba etanool (E 1510); kontsentreeritud fosforhape (E 338) ja süstevesi.
English: - Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Estonian: Ülitundlikkus toimeaine või lõigus 6.1 loetletud mis tahes abiainete suhtes.
English: Very common (1/10) Common
Estonian: Väga sage (1/10) Sage
English: You must inform the nuclear medicine doctor before the administration of Striascan if there is a possibility you might be pregnant, if you have missed your period or if you are breast-feeding.
Estonian: Peate enne Striascani manustamist teavitama nukleaarmeditsiini arsti, kui te võite olla rase, kui teil on menstruatsioon vahele jäänud või kui imetate last.
English: Nausea, dry mouth
Estonian: Iiveldus, suukuivus
English: Absorbed radiation dose µGy/MBq
Estonian: Neeldunud doos µGy / MBq
English: Careful consideration of the activity to be administered is required since an increased radiation exposure is possible in these patients.
Estonian: Manustatavat aktiivsust tuleb hoolikalt jälgida, sest neil patsientidel võib kiirguse ekspositsioon suureneda.
English: Pack size: 1 vial containing 2.5 mL or 5 mL.
Estonian: Pakendi suurus: 1 viaal, mis sisaldab 2,5 ml või 5 ml lahust.
English: I) is excreted in human milk.
Estonian: I) eritub inimese rinnapiima.
English: Careful consideration of the benefit risk ratio in these patients is required since an increased radiation exposure is possible.
Estonian: Kasu/riski suhet tuleb hoolikalt jälgida, sest neil patsientidel võib kiirguse ekspositsioon suureneda.
English: The effective dose (E) resulting from administration of 185 MBq of Striascan injection is 4.6 mSv (per 70 kg individual).
Estonian: 185 MBq Striascani süstimisel on efektiivne annus (E) 4,6 mSv (ühe 70 kg kaaluva inimese kohta).
English: • You should not breast-feed your child for 3 days after this product is given.
Estonian: • Katkestage imetamine 3 päevaks pärast selle ravimpreparaadi saamist.
English: • bupropion (used to treat depression (sadness))
Estonian: • bupropioon (depressiooniravim)
English: Acetic acid, glacial (E 260) Sodium acetate, trihydrate (E 262) Ethanol, anhydrous (E 1510) Phosphoric acid, concentrated (E 338) Water for injections
Estonian: Jää-äädikhape (E 260) Naatriumatsetaattrihüdraat (E 262) Etanool, veevaba (E 1510) Fosforhape, kontsentreeritud (E 338) Süstevesi
English: I) in determining probable DLB from non-DLB ranged from 75.0% to 80.2% and specificity from 88.6% to 91.4%.
Estonian: I) tundlikkuse väärtused tõenäolise Lewy kehadega dementsuse eristamisel muudest kui Lewy kehadega dementsustest olid vahemikus 75,0% kuni 80,2% ja spetsiifilisus 88,6% kuni 91,4%.
English: I): 74 MBq/mL at reference time
Estonian: I): 74 MBq/ml referentsajal .
English: Striascan 74 MBq/mL solution for injection ioflupane (
Estonian: Striascan 74 MBq/ml süstelahus joflupaan (
English: This has been reported among patients receiving this product into a small vein.
Estonian: Seda on täheldatud selle ravimpreparaadi süstimisel väikestesse veenidesse.
English: What Striascan is and what it is used for What you need to know before Striascan is used How Striascan is used
Estonian: Mis ravim on Striascan ja milleks seda kasutatakse Mida on vaja teada enne Striascan'i kasutamist Kuidas Striascan'i kasutada Võimalikud kõrvaltoimed Kuidas Striascan'i säilitada Pakendi sisu ja muu teave
English: Handling and disposal - see package leaflet.
Estonian: Käsitsemise ja hävitamise kohta vt pakendi infoleht.
English: Blood pressure decreased
Estonian: Vererõhu langus
English: These include: - amfetamine, - benzatropine, - bupropion, - cocaine, - mazindol, - methylphenidate, - phentermine and - sertraline.
Estonian: bupropioon, - kokaiin, - masindool, - metüülfenidaat, - fentermiin ja - sertraliin.
English: 185 MBq / vial DD/MM/YYYY xx h xx CET 74 MBq / mL DD/MM/YYYY xx h xx CET
Estonian: 185 MBq viaalis PP/KK/AAAA xx h xx CET 74 MBq / ml PP/KK/AAAA xx h xx CET
English: - If you have any further questions, ask your nuclear medicine doctor who will supervise the procedure.
Estonian: - Kui teil on lisaküsimusi, pidage nõu oma nukleaarmeditsiini arstiga, kes teie protseduuri jälgib.
English: What Striascan looks like and contents of the pack Striascan is a colourless solution for injection, supplied in a single amber 15 mL glass vial sealed with a rubber closure and metal overseal.
Estonian: Striascan on värvitu süstelahus, mida tarnitakse ühes 15 ml merevaiguvärvi klaasist viaalis, mis on suletud kummikorgi ja metallsulguriga.
English: Medicinal products shown in animal studies not to interfere with Striascan imaging include pergolide.
Estonian: Loomadega läbi viidud ravimuuringutes on näidatud, et ka pergoliid ei mõjuta Striascani piltdiagnostikat.
English: If you have any further questions on the use of this medicine, ask your nuclear medicine doctor who supervises the procedure.
Estonian: Kui teil on lisaküsimusi selle ravimi kasutamise kohta, pidage nõu oma protseduuri kontrolliva nukleaarmeditsiini arstiga.
English: How Striascan is used
Estonian: Kuidas Striascani kasutada
English: Each 2.5 mL single dose vial contains 185 MBq ioflupane (
Estonian: Iga 2,5 ml üheannuseline viaal sisaldab referentsajal 185 MBq joflupaani (
English: 370 MBq / vial at ref. (see outer label) 74 MBq / mL
Estonian: 370 MBq/viaal referentsmõõtmisel (vt välist etiketti) 74 MBq/ml
English: 80.2% and specificity from 81.3% to 83.9% when the possible DLB patients were included as non-DLB patients.
Estonian: I) tundlikkuse väärtused vahemikus 75,0% kuni 80,2% ja spetsiifilisus vahemikus 81,3% kuni 83,9%, kui ka võimaliku Lewy kehade dementsusega patsiente loeti ilma Lewy kehade dementsuseta patsientideks.
English: - Hypersensitivity (allergic) - Shortness of breath - Redness of the skin - Itching - Rash - Hives (urticaria) - Excessive sweating - Vomiting - Low blood pressure - Feeling hot.
Estonian: - ülitundlikkus (allergilisus); - hingeldus; - nahapunetus; - kihelus; - lööve; - kublad (nõgeslööve); - tugev higistamine; - oksendamine; - madal vererõhk; - kuumatunne.
English: For all organs and tissues, 80% is assumed to be excreted with a biological half-time of 58 h, and 20% with a half-time of 1.6 h. It is further assumed that 60% of the injected activity is excreted to the urine, and 40% is excreted to the gastrointestinal tract for all organs and tissues.
Estonian: Kõikide elundite ja kudede puhul eritub eeldatavasti 80% bioloogilise poolestusajaga 58 tundi ning 20% poolestusajaga 1,6 tundi.
English: • amfetamine (used to treat hyperactivity in children and narcolepsy (excessive sleepiness);
Estonian: • amfetamiin (laste hüperaktiivsuse ja narkolepsia (ülemäärase unisuse) ravim; ka narkootikum)
English: Manufacturer name address CIS bio international F-91192 GIF-SUR-YVETTE CEDEX
Estonian: Tootja nimi, aadress CIS bio international F-91192 GIF-SUR-YVETTE CEDEX
English: Striascan will always be used in a hospital or a similar place.
Estonian: Striascani kasutamine lubatud ainult haiglates või teistes raviasutustes.
English: Radiation protection precautions in accordance with national regulations must therefore be taken.
Estonian: Seega kiirituse kaitseks tuleb kasutusele võtta kohalikule seadusandlusele vastavaid ettevaatusabinõusid.
English: Storage of radiopharmaceuticals should be in accordance with national regulation on radioactive materials.
Estonian: Radiofarmatseutikume tuleb hoida radioaktiivseid materjale käsitlevate riiklike eeskirjade kohaselt.
English: Volume: 2.5 mL
Estonian: Maht: 2,5 ml
English: Bone surfaces Brain
Estonian: Neerupealised Luu pealispind Aju
English: Since this product is given by a doctor under controlled conditions, it is unlikely that you will get an overdose.
Estonian: Kui teile manustatakse Striascani rohkem kui ette nähtud Et seda ravimpreparaati annab teile arst piiritletud tingimustes, on ülemäärase annuse saamine ebatõenäoline.
English: What Striascan contains - The active substance is ioflupane (
Estonian: Mida Striascan sisaldab • Toimeaine on joflupaan (
English: 185 MBq / vial at ref. (see outer label) 74 MBq / mL
Estonian: 185 MBq / viaal referentsmõõtmisel (vt välist etiketti) 74 MBq / ml
English: 370 MBq / vial DD/MM/YYYY xx h xx CET 74 MBq / mL DD/MM/YYYY xx h xx CET
Estonian: 370 MBq / viaalis PP/KK/AAAA xx h xx CET 74 MBq / mL PP/KK/AAAA xx h xx CET
English: It is not known whether ioflupane (
Estonian: Ei ole teada, kas joflupaani (
English: EXP: 7 h post-ref.
Estonian: Kõlblik kuni: 7 tundi peale referentsmõõtmist.
English: Uncommon (1/1,000 to <1/100) Rare
Estonian: Aeg-ajalt (1/1000 kuni <1/100) Harv (1/10 000 kuni <1/1000) Väga harv (<1/10 000)
English: Contaminated material must be disposed of as radioactive waste via an authorised route.
Estonian: Saastunud materjalid tuleb kõrvaldada vastavalt kohalikule seadusandlusele kui radioaktiivsed jäätmed.
English: Striascan contains the active substance ioflupane (
Estonian: Striascan sisaldab toimeainena joflupaani (
English: Striascan 74 MBq/mL solution for injection
Estonian: Striascan 74 MBq/ml süstelahus
English: EXP: 20 h post-ref.
Estonian: Kõlblik kuni: 20 tundi peale referentsmõõtmist.
English: Volume: 5 mL
Estonian: Maht: 5 mL
English: Small intestine wall Colon wall (Upper large intestine wall ) (Lower large intestine wall) Heart wall
Estonian: Peensoole sein Käärsoole sein (Jämesoole ülaosa sein) (Jämesoole alaosa sein) Südame sein Neerud
English: I) you are given is passed into breast milk.
Estonian: • Toitke last sel ajalimiku piimaseguga.
English: These include:
Estonian: I) seoses on täheldatud järgmisi kõrvaltoimeid:
English: Striascan must not be used
Estonian: Ärge kasutage Striascani:
English: Organ
Estonian: Erirühmad
English: Do not use this medicine after the expiry date which is stated on the labels after EXP. Hospital staff will ensure that the product is stored and thrown away correctly and not used after the expiry date stated on the label.
Estonian: Ärge kasutage seda ravimit pärast kõlblikkusaega, mis on märgitud etiketil.
English: Vial - 5 mL presentation
Estonian: Viaal - 5 ml
English: Metal Box / Lead Pot - 2.5 mL presentation
Estonian: Metallkarp / pliianum - 2,5 ml
English: Each mL of solution contains 74 MBq of ioflupane (
Estonian: Iga ml lahust sisaldab referentsajal 74 MBq joflupaani (
English: Metal Box / Lead Pot - 5 mL presentation
Estonian: metallkarp / pliianum - 5 ml
English: Adverse reaction Preferred term
Estonian: MedDRA organsüsteemi klass Kõrvaltoimete Eelistatud termin
English: Each 5 mL single dose vial contains 370 MBq ioflupane (
Estonian: Iga 5 ml üheannuseline viaal sisaldab referentsajal 370 MBq joflupaani (
English: Vial - 2.5 mL presentation
Estonian: Viaal - 2,5 ml
English: Administration of 185 MBq of ioflupane (
Estonian: 185 MBq joflupaani (
English: Store in the original lead shielding.
Estonian: Hoida originaalses pliivarjestusega anumas.
English: Distribution Ioflupane (
Estonian: Jaotumine Joflupaani (
English: This is because the child may receive some of the radioactivity.
Estonian: Teie laps võib saada selle kasutamisel kiirguseannuse.
English: How Striascan is stored
Estonian: Kuidas Striascani säilitada
English: I) adopted by ICRP 128 ((International Commission on Radiological Protection ,2015) assumes initial uptake of 31% of the administered activity in the liver, 11% in the lungs, and 4% in the brain.
Estonian: 31% manustatud aktiivsuse esialgset seondumist maksas, 11% kopsudes ja 4% ajus.
English: At the chemical concentrations used for diagnostic examinations, Striascan does not appear to have any pharmacodynamic activity.
Estonian: Farmakodünaamiliste toimete ilmnemine ei ole Striascani diagnostikas kasutatavate kontsentratsioonide manustamisel tõenäoline.
English: Name and address of the manufacturer(s) responsible for batch release CIS BIO International
Estonian: Ravimipartii kasutamiseks vabastamise eest vastutava(te) tootja(te) nimi ja aadress
English: Non-clinical data for ioflupane reveal no special hazard for humans based on conventional studies of safety pharmacology, single and repeated dose toxicity and genotoxicity.
Estonian: Farmakoloogilise ohutuse, ühekordse ja korduvtoksilisuse ning genotoksilisuse mittekliinilised uuringud joflupaani kohta ei ole näidanud kahjulikku toimet inimesele.
English: Dizziness, formication (paraesthesia), dysgeusia
Estonian: Pearinglus, “sipelgate jooksmise“ tunne (paresteesia), maitsehäire
English: I) are listed below according to ICRP 128.
Estonian: I) hinnangulised imendunud kiirgusdoosid ICRP 128 järgi, mida võib täheldada preparaadi intravenoossel manustamisel keskmisele täiskasvanud patsiendile (70 kg).
English: F-91192 Gif-sur-Yvette Cedex FRANCE
Estonian: 91192 Gif-sur-Yvette Cedex PRANTSUSMAA
English: ioflupane (
Estonian: Joflupaaniga (
English: Feeling hot
Estonian: Kusepõie sein Emakas
English: Any ioflupane (
Estonian: joflupaan (
English: Organ uptake
Estonian: Organite kaudu omastamine
English: Thymus
Estonian: I LISA
English: The European Commission granted a marketing authorisation valid throughout the European Union for Zometa on 20 March 2001.
Estonian: Euroopa Komisjon andis Zometa müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 20. märtsil
English: What measures are being taken to ensure the safe and effective use of Zometa?
Estonian: Mis meetmed võetakse, et tagada Zometa ohutu ja efektiivne kasutamine?
English: A risk management plan has been developed to ensure that Zometa is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Zometa võimalikult ohutu kasutamine.
English: The full EPAR for Zometa can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Zometa kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Other information about Zometa
Estonian: Muu teave Zometa kohta
English: Zometa should not be used in pregnant or breastfeeding women.
Estonian: Zometat ei tohi kasutada raseduse ja imetamise ajal.
English: Osteonecrosis of the jaw (damage to the bones of the jaw, which could lead to pain, sores in the mouth or loosening of teeth) has been reported uncommonly (seen in between 1 and 10 patients in 1,000).
Estonian: Lõualuu osteonekroosist (lõualuude kahjustus, mis võib tekitada valu, suuhaavandeid või hammaste logisemist) on teatatud harva (esinenud 1-10 patsiendil 1000st).
English: The CHMP decided that Zometa's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Zometa kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: The main measure of effectiveness was the number of patients who developed at least one new ‘skeletal event' over 13 months.
Estonian: Efektiivsuse põhinäitaja oli patsientide arv, kellel tekkis 13 kuu jooksul vähemalt üks uus luukahjustus.
English: Why has Zometa been approved?
Estonian: Miks Zometa heaks kiideti?
English: The usual dose of Zometa is one infusion of 4 mg over at least 15 minutes.
Estonian: Zometa tavaannus on 4 mg, mida manustatakse vähemalt 15 minutit kestva ühekordse infusioonina.
English: The main measure of effectiveness was the number of patients whose calcium levels had returned to normal within 10 days after treatment.
Estonian: Efektiivsuse põhinäitaja oli nende patsientide arv, kelle kaltsiumisisaldus veres normaliseerus 10 päeva jooksul pärast ravi.
English: The most common side effect with Zometa (seen in more than 1 patient in 10) is hypophosphataemia (low blood phosphate levels).
Estonian: Zometa kõige sagedam kõrvalnäht (esinenud enam kui 1 patsiendil 10st) on hüpofosfateemia (vere fosforivaegus).
English: In the third study, Zometa was as effective as pamidronate: 44% of the patients receiving Zometa had at least one skeletal event, compared with 46% of those receiving pamidronate.
Estonian: Kolmandas uuringus oli Zometa sama tõhus kui pamidronaat: luukahjustusega patsientide hulk oli Zometa ravirühmas 44% ja pamidronaadi ravirühmas 46%.
English: It is available as a powder (4mg) and solvent, and as a concentrate (4mg/5ml), both of which are made up into a solution for infusion (drip into a vein), and as a pre-prepared solution for infusion (4mg/100ml).
Estonian: Seda turustatakse infusioonilahuse (veeni tilgutatava lahuse) pulbri (4 mg) ja lahustina või kontsentraadina (4 mg/5 ml) ning valmis infusioonilahusena (4 mg/100 ml).
English: In addition, the company that markets Zometa will provide a card to inform patients about the risk of osteonecrosis of the jaw and to instruct them to contact their doctor if they experience symptoms.
Estonian: Lisaks varustab Zometa turustaja patsiendid teabekaardiga, milles neid teavitatakse lõualuu osteonekroosi riskist ning soovitatakse neil sümptomite ilmnemisel arsti poole pöörduda.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Zometa, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Zometa omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: For the full list of all side effects reported with Zometa, see the package leaflet.
Estonian: Zometa kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: Zometa was compared with placebo (a dummy treatment) in two of the studies, and with pamidronate (another bisphosphonate) in the third.
Estonian: Zometat võrreldi kahes uuringus platseeboga (näiv ravim) ja kolmandas uuringus pamidronaadiga (samuti bisfosfonaat).
English: For more information about treatment with Zometa, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Zometaga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: This is a summary of the European public assessment report (EPAR) for Zometa.
Estonian: See on ravimi Zometa Euroopa avaliku hindamisaruande kokkuvõte.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Zometa.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: Zoledronic acid
Estonian: Zometa solendroonhape
English: In patients with hypercalcaemia, Zometa was more effective than pamidronate.
Estonian: Hüperkaltseemiaga patsientidele mõjus Zometa efektiivsemalt kui pamidronaat.
English: The active substance in Zometa, zoledronic acid, is a bisphosphonate.
Estonian: Zometa toimeaine soledroonhape on bisfosfonaat.
English: Zometa can also be used to treat the hypercalcaemia caused by tumours.
Estonian: Zometat tohib kasutada ka kasvajast põhjustatud hüperkaltseemia raviks.
English: Zometa must only be used by a doctor who has experience in the use of this type of medicine given into a vein.
Estonian: Zometat tohib patsiendile manustada üksnes seda tüüpi veenisiseste ravimite kasutamises kogenud arst.
English: Looking at the results of the two studies together, 88% of the patients receiving Zometa had normal calcium levels within 10 days after treatment, compared with 70% of those receiving pamidronate.
Estonian: Kahe uuringu tulemuste koondanalüüsis oli patsiente, kelle kaltsiumisisaldus veres normaliseerus 10 päeva jooksul pärast ravi, Zometa ravirühmas 88% ja pamidronaadi ravirühmas 70%.
English: What is the risk associated with Zometa?
Estonian: Mis riskid Zometaga kaasnevad?
English: In the first two studies of patients with bone metastases, the number of patients who developed a new skeletal event was lower with Zometa (33 to 38%) than with placebo (44%).
Estonian: Kahes esimeses luumetastaasidega patsientide uuringus tekkis Zometa ravirühmas vähem uusi luukahjustusi kui platseeborühmas (vastavalt 33-38% ja 44%).
English: Zometa is a medicine that contains the active substance zoledronic acid.
Estonian: Zometa on ravim, mis sisaldab toimeainena soledroonhapet.